Association Between Routine Blood Biomarkers and Clinical Phenotypes and Exacerbations in Chronic Obstructive Pulmonary Disease

References

• DecramerM, JanssensW, MiravitllesM. Chronic obstructive pulmonary disease. Lancet. 2012;379(9823):1341–1351. doi:10.1016/S0140-6736(11)60968-922314182
   PubMed Web of Science ®Google Scholar
• GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736–1788.30496103
   PubMed Web of Science ®Google Scholar
• MacNeeW. Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(4):258–266. doi:10.1513/pats.200504-045SR16267346
   PubMedGoogle Scholar
• WalterRE, WilkJB, LarsonMG, et al. Systemic inflammation and COPD: the Framingham Heart Study. Chest. 2008;133(1):19–25. doi:10.1378/chest.07-005817908709
   PubMed Web of Science ®Google Scholar
• AnzuetoA, MiravitllesM. Chronic obstructive pulmonary disease exacerbations: a need for action. Am J Med. 2018;131:15–22. doi:10.1016/j.amjmed.2018.05.00329777660
   PubMed Web of Science ®Google Scholar
• WedzichaJA, MiravitllesM, HurstJR, et al. Management of COPD exacerbations: an European Respiratory Society/American Thoracic Society (ERS/ATS) guideline. Eur Respir J. 2017;49:1600791. doi:10.1183/13993003.00791-201628298398
   PubMed Web of Science ®Google Scholar
• BradfordE, JacobsonS, VarastehJ, et al. The value of blood cytokines and chemokines in assessing COPD. Respir Res. 2017;18:180. doi:10.1186/s12931-017-0662-229065892
   PubMed Web of Science ®Google Scholar
• FanerR, Tal-SingerR, RileyJH, et al. ECLIPSE Study Investigators. Lessons from ECLIPSE: a review of COPD biomarkers. Thorax. 69;2014:666–672. doi:10.1136/thoraxjnl-2013-20477824310110
   PubMed Web of Science ®Google Scholar
• MillerBE, Tal-SingerR, RennardSI, et al. Plasma fibrinogen qualification as a drug development tool in chronic obstructive pulmonary disease. Perspective of the chronic obstructive pulmonary disease biomarker qualification consortium. Am J Respir Crit Care Med. 2016;193(6):607–613. doi:10.1164/rccm.201509-1722PP26745765
   PubMed Web of Science ®Google Scholar
• YaoC, LiuX, TangZ. Prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio for hospital mortality in patients with AECOPD. Int J Chron Obstruct Pulmon Dis. 2017;12:2285–2290. doi:10.2147/COPD.S14176028814856
   PubMed Web of Science ®Google Scholar
• AksoyE, KarakurtZ, GungorS, et al. Neutrophil to lymphocyte ratio is a better indicator of COPD exacerbation severity in neutrophilic endotypes than eosinophilic endotypes. Int J Chron Obstruct Pulmon Dis. 2018;13:2721–2730. doi:10.2147/COPD30233162
   PubMed Web of Science ®Google Scholar
• XiongW, XuM, ZhaoY, WuX, PudasainiB, LiuJM. Can we predict the prognosis of COPD with a routine blood test? Int J Chron Obstruct Pulmon Dis. 2017;12:615–625. doi:10.2147/COPD.S12404128243079
   PubMed Web of Science ®Google Scholar
• BestallJC, PaulEA, GarrodR, GarnhamR, JonesPW, WedzichaJA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581–586. doi:10.1136/thx.54.7.58110377201
   PubMed Web of Science ®Google Scholar
• Soler-CataluñaJJ, Martínez-GarcíaMA, SánchezL, PerpiñaM, RománP. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med. 2009;103:692–699. doi:10.1016/j.rmed.2008.12.00519131231
   PubMed Web of Science ®Google Scholar
• JonesPW, HardingG, BerryP, WiklundI, ChenWH, Kline LeidyN. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34(3):648–654. doi:10.1183/09031936.0010250919720809
   PubMed Web of Science ®Google Scholar
• MiravitllesM, Soler-CataluñaJJ, CalleM, et al. Spanish guidelines for management of chronic obstructive pulmonary disease (GesEPOC) 2017. Pharmacological treatment of stable Phase. Arch Bronconeumol. 2017;53(6):324–335. doi:10.1016/j.arbr.2017.03.01728477954
   PubMed Web of Science ®Google Scholar
• PlazaV, ÁlvarezF, CalleM, et al. Consensus on the Asthma-COPD Overlap Syndrome (ACOS) between the Spanish COPD guidelines (GesEPOC) and the Spanish Guidelines on the Management of Asthma (GEMA). Arch Bronconeumol. 2017;53(8):443–449. doi:10.1016/j.arbres.2017.04.00228495077
   PubMed Web of Science ®Google Scholar
• SinghD, AgustiA, AnzuetoA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164. doi:10.1183/13993003.00164-201930846476
   PubMed Web of Science ®Google Scholar
• Soler-CataluñaJJ, Martínez-GarcíaMA, Román SánchezP, SalcedoE, NavarroM, OchandoR. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925–931. doi:10.1136/thx.2005.04052716055622
   PubMed Web of Science ®Google Scholar
• DollH, MiravitllesM. Quality of life in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literature. Pharmacoeconomics. 2005;23:345–363. doi:10.2165/00019053-200523040-0000515853435
   PubMed Web of Science ®Google Scholar
• HurstJR, VestboJ, AnzuetoA, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;63:1128–1138. doi:10.1056/NEJMoa0909883
   Web of Science ®Google Scholar
• YohannesAM, ErshlerWB. Anemia in COPD: a systematic review of the prevalence, quality of life, and mortality. Respir Care. 2011;56:644–652. doi:10.4187/respcare.0100221276321
   PubMed Web of Science ®Google Scholar
• ChambellanA, ChailleuxE, SimilowskiT. Prognostic value of the hematocrit in patients with severe COPD receiving long-term oxygen therapy. Chest. 2005;128:1201–1208. doi:10.1378/chest.128.3.120116162707
   PubMed Web of Science ®Google Scholar
• Martinez-RiveraC, PortilloK, Muñoz-FerrerA, et al. Anemia is a mortality predictor in hospitalized patients for COPD exacerbation. COPD. 2012;9(3):243–250. doi:10.3109/15412555.2011.64713122360381
   PubMedGoogle Scholar
• Toft-PetersenAP, Torp-PedersenC, WeinreichUM, RasmussenBS. Association between hemoglobin and prognosis in patients admitted to hospital for COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:2813–2820. doi:10.2147/COPD27877035
   PubMed Web of Science ®Google Scholar
• ParkSC, KimYS, KangYA, et al. Hemoglobin and mortality in patients with COPD: a nationwide population-based cohort study. Int J Chron Obstruct Pulmon Dis. 2018;13:1599–1605. doi:10.2147/COPD29805259
   PubMed Web of Science ®Google Scholar
• PepysMB, HirschfieldGM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805–1812. doi:10.1172/JCI20031892112813013
   PubMed Web of Science ®Google Scholar
• JingZ, ChunC, NingS, HongZ, BeiH, Wan-ZhenY. Systemic inflammatory Marker CRP was better predictor of readmission for AECOPD than sputum inflammatory Markers. Arch Bronconeumol. 2016;52(3):138–144. doi:10.1016/j.arbres.2015.01.01126002550
   PubMed Web of Science ®Google Scholar
• García-RiveroJL, EsquinasC, BarrechegurenM, et al. Risk factors of poor outcomes after admission for a COPD exacerbation: multivariate logistic predictive models. COPD. 2017;14(2):164–169. doi:10.1080/15412555.2016.126053827983876
   PubMedGoogle Scholar
• LeuzziG, GaleoneC, TavernaF, SuatoniP, MorelliD, PastorinoU. C-reactive protein level predicts mortality in COPD: a systematic review and meta-analysis. Eur Respir Rev. 2017;26(143):160070. doi:10.1183/16000617.0070-201628143876
   PubMed Web of Science ®Google Scholar
• ThomsenM, IngebrigtsenTS, MarottJL, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA. 2013;309:2353–2361. doi:10.1001/jama.2013.573223757083
   PubMed Web of Science ®Google Scholar
• JanciauskieneS, DeLucaDS, BarrechegurenM, WelteT, MiravitllesM. Serum levels of Alpha1-antitrypsin and their relationship with COPD in the General Spanish Population. Arch Bronconeumol. 2020;56(2):76–83. doi:10.1016/j.arbres.2019.03.001
   Web of Science ®Google Scholar
• EllisP, TurnerA. What do alpha-1 antitrypsin levels tell us about chronic inflammation in COPD? Arch Bronconeumol. 2020;56(2):72–73. doi:10.1016/j.arbres.2019.06.010
   Web of Science ®Google Scholar
• NuñezA, SarasateM, LoebE, EsquinasC, MiravitllesM, BarrechegurenM. Practical guide to the identification and diagnosis of asthma-COPD overlap (ACO). COPD. 2019;16:1–7. doi:10.1080/15412555.2019.157580230789039
   PubMedGoogle Scholar
• SuzukiM, MakitaH, KonnoS, et al. Hokkaido COPD cohort study investigators. Asthma-like features and clinical course of chronic obstructive pulmonary disease. An analysis from the Hokkaido COPD Cohort Study. Am J Respir Crit Care Med. 2016;194(11):1358–1365. doi:10.1164/rccm.201602-0353OC27224255
   PubMed Web of Science ®Google Scholar
• SahaS, BrightlingCE. Eosinophilic airway inflammation in COPD. Int J COPD. 2006;1(1):39–47. doi:10.2147/copd.2006.1.issue-1
   Google Scholar
• SaltürkC, KarakurtZ, AdiguzelN, et al. Does eosinophilic COPD exacerbation have a better patient outcome than non-eosinophilic in the intensive care unit? Int J COPD. 2015;10:1837–1846. doi:10.2147/COPD.S88058
   Google Scholar
• KaveriSV, MouthonL, BayryJ. Basophil and nephritis in lupus. N Engl J Med. 2010;363(11):1080–1082. doi:10.1056/NEJMcibr100693620825323
   PubMed Web of Science ®Google Scholar
• Pascual-GonzálezY, López-SánchezM, DorcaJ, SantosS. Defining the role of neutrophil-to-lymphocyte ratio in COPD: a systematic literature review. Int J Chron Obstruct Pulmon Dis. 2018;13:3651–3662. doi:10.2147/COPD30464448
   PubMed Web of Science ®Google Scholar
• MekovE, YanevN, PetkovR, KostadinovD. Neutrophil to lymphocyte ratio in COPD. Thoracic Med. 2018;X(3):8–15.
   Google Scholar
• FawzyA, PutchaN, PaulinLM, et al. SPIROMICS and COPDGene Investigators. Association of thrombocytosis with COPD morbidity: the SPIROMICS and COPDGene cohorts. Respir Res. 2018;19(1):20. doi:10.1186/s12931-018-0717-z.29373977
   PubMed Web of Science ®Google Scholar
• HarrisonMT, ShortP, WilliamsonPA, SinganayagamA, ChalmersJD, SchembriS. Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy? Thorax. 2014;69(7):609–615. doi:10.1136/thoraxjnl-2013-20399624743560
   PubMed Web of Science ®Google Scholar
• KaradenizG, AktoğuS, ErerOF, et al. Predictive value of platelet-to-lymphocyte ratio in exacerbation of chronic obstructive pulmonary disease. Biomark Med. 2016;10:701–710. doi:10.2217/bmm-2016-004627339097
   PubMed Web of Science ®Google Scholar
• KurtipekE, BekciTT, KesliR, SamiSS, TerziY. The role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in exacerbation of chronic obstructive pulmonary disease. J Pak Med Assoc. 2015;65:1283–1287.26627508
   PubMed Web of Science ®Google Scholar
• KumarP, LawS, SriramKB. Evaluation of platelet lymphocyte ratio and 90-day mortality in patients with acute exacerbation of chronic obstructive pulmonary disease. J Thorac Dis. 2017;9(6):1509–1516. doi:10.21037/jtd28740663
   PubMed Web of Science ®Google Scholar